AZD9056

AZD9056 is a potent, selective, orally bioavailable small molecule antagonist of the purinergic receptor P2X7. It was developed primarily for the treatment of inflammatory conditions such as rheumatoid arthritis, Crohn’s disease, osteoarthritis, and chronic obstructive pulmonary disease. The drug acts by inhibiting the P2X7 receptor—a ligand-gated ion channel involved in inflammation and pain—thereby reducing the release of proinflammatory cytokines like IL‑1β and IL‑18. Clinical trials reached phase II for several indications but were discontinued due to insufficient efficacy despite a favorable safety profile. The compound was originally developed by AstraZeneca[1][4][8].

Other names

N-(1-adamantylmethyl)-2-chloro-5-[3-(3-hydroxypropylamino)propyl]benzamide345304-65-6